STOCK TITAN

Pacira BioSciences director tenders 16,654 shares

Available on EDGAR Accepted by SEC EDGAR Learn about SEC filing dates
(Neutral)

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

Form Type
4

Rhea-AI Filing Summary

Pacira BioSciences, Inc. became a wholly owned subsidiary of Viatris Inc. on November 17, 2026, after Peach Purchaser Sub Inc. completed a cash tender offer and merged into Pacira. Director Christopher Christie disposed of 16,654 common shares, each converted into the right to receive $36.50 per share, net of applicable withholding taxes and without interest.

At the merger’s effective time, Christie's restricted stock units covering 6,405 shares were canceled and converted into cash based on the offer price, subject to tax withholding. His options were canceled; options with exercise prices below $36.50 per share converted into cash based on the positive difference between the offer price and exercise price, while options at or above that price were canceled for no consideration. No Rule 10b5-1 plan is reported.

Insider CHRISTIE CHRISTOPHER
Role Director
Type Security Shares Price Value
Disposition Stock Option (Right to Buy) F3 8,027 -- --
Disposition Stock Option (Right to Buy) F3 7,626 -- --
Disposition Stock Option (Right to Buy) F3 8,225 -- --
Disposition Stock Option (Right to Buy) F3 12,179 -- --
Disposition Stock Option (Right to Buy) F3 11,279 -- --
Disposition Stock Option (Right to Buy) F3 10,891 -- --
Disposition Stock Option (Right to Buy) F3 3,334 -- --
Disposition Stock Option (Right to Buy) F3 19,919 -- --
Disposition Stock Option (Right to Buy) F3 25,000 -- --
Tender Offer Common Stock F1 16,654 $36.50 $608K
Disposition Common Stock F2 6,405 $36.50 $234K
Holdings After Transaction: Stock Option (Right to Buy) — 0 options (Direct); Common Stock — 0 shares (Direct)
Holdings Before and After: Stock Option (Right to Buy), 106,480 to 0 options (Direct); Common Stock, 23,059 to 0 shares (Direct)
Footnotes (3)
  1. F1. Disposed of pursuant to the Agreement and Plan of Merger, dated as of October 8, 2026, by and among Pacira BioSciences, Inc. ("Issuer"), Viatris Inc. ("Viatris") and Peach Purchaser Sub Inc. ("Purchaser") (the "Merger Agreement"), pursuant to which Purchaser consummated a cash tender offer (the "Offer") to purchase all of the outstanding shares of Issuer's common stock (the "Shares") for $36.50 per Share, net of applicable withholding taxes and without interest (the "Offer Price"), after which Purchaser merged with and into Issuer with Issuer continuing as the surviving corporation and a wholly owned subsidiary of Viatris (the "Merger"). On November 17, 2026, the effective time of the Merger (the "Effective Time"), each Share was converted into the right to receive the Offer Price.
  2. F2. Pursuant to the Merger Agreement, at the Effective Time, each restricted stock unit award ("RSU") that was outstanding as of immediately prior to the Effective Time, whether vested or unvested, was canceled and converted into the right to receive an amount in cash equal to the product of (i) the total number of Shares issuable in settlement of such RSU, multiplied by (ii) the Offer Price, subject to applicable tax withholdings.
  3. F3. Pursuant to the Merger Agreement, at the Effective Time, each option to purchase Shares ("Option") that was outstanding as of immediately prior to the Effective Time, whether vested or unvested, was canceled and converted into the right to receive an amount in cash equal to the product of (i) the total number of Shares subject to such Option immediately prior to the Effective Time, multiplied by (ii) the excess, if any, of (A) the Offer Price minus (B) the exercise price payable per Share under such Option, subject to applicable tax withholdings. Each Option that was outstanding immediately prior to the Effective Time which had a per Share exercise price greater than or equal to the Offer Price was cancelled at the Effective Time with no consideration payable.
Common shares tendered 16,654 shares Converted into the right to receive the offer price on November 17, 2026.
Cash tender offer price $36.50 per share Net of applicable withholding taxes and without interest.
Shares covered by restricted stock units 6,405 shares The restricted stock units were canceled and converted into cash at the merger effective time, subject to tax withholding.
Option shares and exercise price 8,027 shares at $47.65 per share The exercise price was at or above the $36.50 offer price; the option was canceled for no consideration.
Option shares and exercise price 12,179 shares at $28.68 per share The option was canceled and converted into a right to cash based on the positive difference between the offer price and exercise price.
cash tender offer financial
"consummated a cash tender offer"
A cash tender offer is a public proposal in which an individual or group offers to buy a set number of a company's shares directly from shareholders for a specified cash price during a limited time. It matters to investors because it gives a clear, immediate chance to sell shares at a known price — like a store offering to buy back items at a posted rate — and can affect the stock’s market price, ownership control and liquidity.
Offer Price financial
"the Offer Price, net of applicable withholding taxes and without interest"
The offer price is the amount per share that a company or underwriter sets when selling new stock or bonds to investors, like the price tag on an item in a store. It matters because it determines how much investors must pay, shapes the initial market value of the security, and influences whether demand will be strong or weak — which affects early trading performance and potential returns.
restricted stock unit award financial
"each restricted stock unit award ("RSU") that was outstanding"
A restricted stock unit award is a promise by a company to give an employee a specified number of company shares at a future date if certain conditions are met, such as staying with the company or hitting performance goals. For investors, these awards matter because they can increase the total number of shares outstanding when converted, diluting existing holders, and they align employees’ incentives with shareholders’ interests much like giving a rising bonus that becomes real only after conditions are satisfied.
Effective Time technical
"the effective time of the Merger (the "Effective Time")"
The exact clock time when a regulatory filing, approval, or corporate action formally becomes legally active; from that moment the change is binding and can be acted on. Investors care because the effective time marks when ownership, rights, trading rules, or new securities take effect — like a light switch turning on a contract or transaction — which determines when risks, benefits and market reactions begin.
exercise price financial
"the exercise price payable per Share under such Option"
The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.
Merger Agreement regulatory
"the Agreement and Plan of Merger (the "Merger Agreement")"
A merger agreement is a binding contract that lays out the exact terms for two companies to combine, including the price, what each side will deliver, and the conditions that must be met before the deal is completed. Investors care because it sets the timetable, payouts and risks — like a blueprint or prenup that shows whether the deal is likely to close, how ownership will change, and what could cancel or alter the payout they expect.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How many PCRX shares did director Christopher Christie tender?

Director Christopher Christie tendered 16,654 common shares on November 17, 2026, converting them into the right to receive $36.50 per share, net of applicable withholding taxes and without interest. No Rule 10b5-1 plan is reported.

What happened to Christopher Christie's PCRX options and RSUs?

At the November 17, 2026 merger effective time, his restricted stock units covering 6,405 shares were canceled and converted into cash based on the $36.50 offer price, subject to tax withholding. Options below $36.50 in exercise price converted into cash based on the positive difference; options at or above $36.50 were canceled for no consideration.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
X
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
CHRISTIE CHRISTOPHER

(Last)(First)(Middle)
C/O PACIRA BIOSCIENCES, INC.
2000 SIERRA POINT PARKWAY, SUITE 900

(Street)
BRISBANE CALIFORNIA 94005

(City)(State)(Zip)

UNITED STATES

(Country)
2. Issuer Name and Ticker or Trading Symbol
Pacira BioSciences, Inc. [ PCRX ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
XDirector10% Owner
Officer (give title below)Other (specify below)
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
11/17/2026
6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Common Stock11/17/2026U(1)16,654D$36.56,405D
Common Stock11/17/2026D(2)6,405D$36.50D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Stock Option (Right to Buy)$47.6511/17/2026D8,027 (3)06/09/2030Common Stock8,027(3)0D
Stock Option (Right to Buy)$60.9611/17/2026D7,626 (3)06/09/2031Common Stock7,626(3)0D
Stock Option (Right to Buy)$59.3911/17/2026D8,225 (3)06/08/2032Common Stock8,225(3)0D
Stock Option (Right to Buy)$28.6811/17/2026D12,179 (3)06/12/2034Common Stock12,179(3)0D
Stock Option (Right to Buy)$24.3411/17/2026D11,279 (3)06/11/2035Common Stock11,279(3)0D
Stock Option (Right to Buy)$23.4211/17/2026D10,891 (3)06/10/2036Common Stock10,891(3)0D
Stock Option (Right to Buy)$42.5411/17/2026D3,334 (3)07/02/2029Common Stock3,334(3)0D
Stock Option (Right to Buy)$37.1611/17/2026D19,919 (3)09/18/2029Common Stock19,919(3)0D
Stock Option (Right to Buy)$42.5411/17/2026D25,000 (3)05/02/2028Common Stock25,000(3)0D
Explanation of Responses:
1. Disposed of pursuant to the Agreement and Plan of Merger, dated as of October 8, 2026, by and among Pacira BioSciences, Inc. ("Issuer"), Viatris Inc. ("Viatris") and Peach Purchaser Sub Inc. ("Purchaser") (the "Merger Agreement"), pursuant to which Purchaser consummated a cash tender offer (the "Offer") to purchase all of the outstanding shares of Issuer's common stock (the "Shares") for $36.50 per Share, net of applicable withholding taxes and without interest (the "Offer Price"), after which Purchaser merged with and into Issuer with Issuer continuing as the surviving corporation and a wholly owned subsidiary of Viatris (the "Merger"). On November 17, 2026, the effective time of the Merger (the "Effective Time"), each Share was converted into the right to receive the Offer Price.
2. Pursuant to the Merger Agreement, at the Effective Time, each restricted stock unit award ("RSU") that was outstanding as of immediately prior to the Effective Time, whether vested or unvested, was canceled and converted into the right to receive an amount in cash equal to the product of (i) the total number of Shares issuable in settlement of such RSU, multiplied by (ii) the Offer Price, subject to applicable tax withholdings.
3. Pursuant to the Merger Agreement, at the Effective Time, each option to purchase Shares ("Option") that was outstanding as of immediately prior to the Effective Time, whether vested or unvested, was canceled and converted into the right to receive an amount in cash equal to the product of (i) the total number of Shares subject to such Option immediately prior to the Effective Time, multiplied by (ii) the excess, if any, of (A) the Offer Price minus (B) the exercise price payable per Share under such Option, subject to applicable tax withholdings. Each Option that was outstanding immediately prior to the Effective Time which had a per Share exercise price greater than or equal to the Offer Price was cancelled at the Effective Time with no consideration payable.
Remarks:
/s/ Kristen Williams, Attorney-in-Fact11/17/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Keep reading